Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Quality of life in sexual minorities following prostate cancer treatment

Patients with prostate cancer from sexual minority groups experience considerably worse quality of life following prostate cancer treatment than heterosexual patients. Improved inclusivity as well as cultural humility training at the physician, institution and system levels are warranted to address inequalities in quality-of-life outcomes.

This is a preview of subscription content

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Fig. 1: Quality-of-life aspects impaired in patients from sexual minority groups after prostate cancer treatment.

References

  1. Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209–249 (2021).

    Article  Google Scholar 

  2. Rosser, B. R. S. et al. Understanding prostate cancer in gay, bisexual, and other men who have sex with men and transgender women: a review of the literature. Curr. Sex. Health Rep. 11, 430–441 (2019).

    Article  Google Scholar 

  3. Rosser, B. R. S. et al. Health disparities of sexual minority patients following prostate cancer treatment: results from the Restore-2 study. Front. Oncol. 12, 812117 (2022).

    Article  Google Scholar 

  4. Ussher, J. M. et al. Health-related quality of life, psychological distress, and sexual changes following prostate cancer: a comparison of gay and bisexual men with heterosexual men. J. Sex. Med. 13, 425–434 (2016).

    Article  Google Scholar 

  5. Haggart, R. et al. Comorbidity prevalence and impact on quality of life in gay and bisexual men following prostate cancer treatment. Sex. Med. 9, 100439 (2021).

    Article  Google Scholar 

  6. McInnis, M. K. & Pukall, C. F. Sex after prostate cancer in gay and bisexual men: a review of the literature. Sex. Med. Rev. 8, 466–472 (2020).

    Article  Google Scholar 

  7. Polter, E. J. et al. Creation and psychometric validation of the sexual minorities and prostate cancer scale (SMACS) in sexual minority patients-the Restore-2 study. J. Sex. Med. 19, 529–540 (2022).

    Article  Google Scholar 

  8. Lee, T. K. et al. Development of a sexual quality of life questionnaire for men-who-have-sex-with-men with prostate cancer. Sex. Med. 10, 100480 (2022).

    Article  Google Scholar 

  9. Alpert, A. et al. What exactly are we measuring? Evaluating sexual and gender minority cultural humility training for oncology care clinicians. J. Clin. Oncol. 38, 2605–2609 (2020).

    Article  Google Scholar 

  10. Berrahou, I. K., Snow, A., Swanson, M. & Obedin-Maliver, J. Representation of sexual and gender minority people in patient nondiscrimination policies of cancer centers in the United States. J. Natl Compr. Cancer Netw. https://doi.org/10.6004/jnccn.2021.7078 (2022).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to David J. Benjamin.

Ethics declarations

Competing interests

A.R. declares stock and other ownership interests: ECOM Medical; consulting or advisory role: Exelixis, AstraZeneca, Bayer, Pfizer, Novartis, Genentech, Bristol Myers Squibb, EMD Serono, Immunomedics and Gilead Sciences; speakers’ bureau: Janssen, Astellas Medivation, Pfizer, Novartis, Sanofi, Genentech/Roche, Eisai, AstraZeneca, Bristol Myers Squibb, Amgen, Exelixis, EMD Serono, Merck, Seattle Genetics/Astellas, Myovant Sciences, Gilead Sciences and AVEO; research funding: Genentech, Exelixis, Janssen, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Macrogenics, Astellas Pharma, BeyondSpring Pharmaceuticals, BioClin Therapeutics, Clovis Oncology, Bavarian Nordic, Seattle Genetics, Immunomedics and Epizyme; and travel, accommodations and/or expenses: Genentech, Prometheus, Astellas Medivation, Janssen, Eisai, Bayer, Pfizer, Novartis, Exelixis and AstraZeneca. D.J.B. declares no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Benjamin, D.J., Rezazadeh, A. Quality of life in sexual minorities following prostate cancer treatment. Nat Rev Urol 19, 323–324 (2022). https://doi.org/10.1038/s41585-022-00601-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41585-022-00601-5

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing